TABLE 6.
Serum plasmalogen/phosphatide indices in University of Pennsylvania cohort: associations with CSF AD biomarkers
| CSF Total tau (Ttau) |
CSF Aβ1–42 |
log10(CSF Ttau/Aβ1–42) |
||||
|---|---|---|---|---|---|---|
| Ratio/Index | β (95% CI) | P value | β (95% CI) | P value | β (95% CI) | P value |
| PBV | −6.444 (−19.997, 7.110) | 0.348 | −4.118 (−27.553, 19.318) | 0.728 | −0.011 (−0.103, 0.080) | 0.806 |
| PL-PX | 0.836 (−10.256, 11.927) | 0.882 | −9.159 (−28.192, 9.873) | 0.342 | 0.033 (−0.041, 0.107) | 0.383 |
| PL/PE | −12.040 (−22.932, −1.148) | 0.031 | 6.949 (−12.185, 26.083) | 0.473 | −0.068 (−0.141, 0.005) | 0.068 |
Notes: P-values were estimated from linear regression models and adjusted for age and sex. Results from 3A were further adjusted for APOE e4 carrier status. Due to small number of subjects with genotyping in UPenn cohort, results presented are not adjusted for APOE e4. Above results were not adjusted for concomitant medications. Three indices were calculated to assess the following: a) PL-PX: index of biosynthesis and/or remodeling of ethanolamine plasmalogens using mean of PL226/PL224, PL205/PL224, and PL205/PL226; b) PL/PE: index of ratio of omega-3 fatty acid-containing plasmalogens to the DHA-containing phosphatide PtdEtn 16:0/22:6 using mean of PL226/PE226 and PL205/PE226; and c) PBV: overall composite index of plasmalogen biosynthesis and/or remodeling using a mean of all five ratios contributing to index (a) and index (b).
Abbreviations: Aβ1–42, amyloid beta peptide, residues 1–42; CSF, cerebrospinal fluid; Ttau, total-tau.